Netflix has finally shared the official trailer for His & Hers, the upcoming crime thriller drama, starring Marvel vets Tessa ...
Zacks Investment Research on MSN
Hims & Hers plunges 29.1% in 6 months: Time to hold the stock or sell?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its ...
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...
Zacks Investment Research on MSN
Hims & Hers expands weight-management program to the United Kingdom
Hims & Hers HIMS recently announced that it is expanding access to its comprehensive Weight Loss Program to customers in the ...
Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo Nordisk’s ...
The trajectory of well-known health and wellness platform Hims & Hers is one that most entrepreneurs and investors would hope for. Not even six years old, the company has for the most part experienced ...
The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...
Netflix's upcoming "seductive and twisty" series His & Hers starring Tessa Thompson has just released its first trailer. Also ...
Medical Device Network on MSN
Hims & Hers Health signs agreement to acquire YourBio Health
Hims & Hers Health has signed a definitive agreement to acquire US-based YourBio Health, which provides capillary blood ...
Hims and Hers first announced its expansion into Canada in early July, taking the opportunity as Danish pharmaceutical giant ...
The market is just starting to notice the great things this small-cap stock has been doing for a while now. It often feels like you've missed the boat when you sit there reading about another stock ...
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results